Effect of terguride on insulin binding, insulinaemia, glucose tolerance and hyperlipaemia in lean SHR Koletsky rats
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
9730050
Knihovny.cz E-resources
- MeSH
- Dopamine Agonists pharmacology MeSH
- Erythrocytes metabolism MeSH
- Glucose Tolerance Test MeSH
- Hyperlipidemias blood physiopathology MeSH
- Insulin blood MeSH
- Rats MeSH
- Lisuride analogs & derivatives pharmacology MeSH
- Rats, Inbred SHR MeSH
- Eating drug effects MeSH
- Body Weight drug effects MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Male MeSH
- Female MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Dopamine Agonists MeSH
- dironyl MeSH Browser
- Insulin MeSH
- Lisuride MeSH
Glucose tolerance, insulin binding to erythrocytes, insulinaemia, plasma total cholesterol, plasma triglycerides, weight of fat pads, food consumption and body weight changes were studied in genetically hypertensive lean Koletsky rats. Long-term treatment with dopaminergic agonist terguride (0.2 mg/kg/day) normalized glucose tolerance and increased the percentage of bound insulin to erythrocytes in both sexes. Terguride decreased insulinaemia, cholesterolaemia, fat pads and body weight only in female rats. Food consumption was not influenced by terguride over the injection period.
